Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

HIV/AIDS Therapy: Studies from D.Harte and colleagues reveal new findings on HIV/AIDS therapy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Europe’s Tissue Industry Supports Millions of...

New data highlights the sector’s economic contribution and essential...

Personalized Medicine Advancing Targeted Treatment Path

A comprehensive analysis of how genomic insights, biomarker research, and data-driven precision therapies are transforming the traditional one-size-fits-all medical model into highly individualized patient care.

Beyond the Waitlist: How a Single...

For many families, the path to an autism diagnosis...

A new study, ' Immunosuppression among HIV-1-positive patients attending for care: experience from two large HIV centers in the UK ' is revealed by D. Harte and Colleagues.

"The aim of the study was to describe the prevalence of and examine the factors associated with immunosuppression (CD4 <200 cells/microL) among HIV-infected patients attending two large inner London treatment centers. Patients attending for care who had a CD4 count <200 cells/microL during a 6-month period (1 January to 30 June 2007) were identified from the UK national CD4 surveillance database," scientists in London, the United Kingdom report.

"Corresponding case notes were reviewed and factors associated with the most recent immunosuppressive episode examined. Patients either previously had a CD4 count >200 cells/microL at any time under follow-up which had decreased (group A) or never had a CD4 count >200 cells/microL (group B; late presenters). Of 4589 patients, 10.2% (467) had at least one CD4 count <200 cells/microL. In group A (60.1% of patients), 70.4% were not receiving antiretroviral therapy (ART) at the time at which the CD4 count fell to <200 cells/microL. Reasons included: treatment interruption (TI; 32.6%), patient declined ART (20.2%), infrequent attendance (19.1%), physician delay in offer (23.1%) and transient CD4 cell count decrease (3.9%). Among those receiving ART, one in three had poor adherence. In group B, 92.3% had started ART after presentation: most had recently started and were responding virologically. AIDS-defining diagnoses occurred in the year preceding the decrease in CD4 cell count in 12.6% of patients in group A and 33.3% of those in group B. The majority of patients became immunosuppressed while under care "wrote D. Harte and colleagues.

D. Harte and colleagues concluded: "Our findings suggest that, in addition to strategies aimed at earlier diagnosis, there are further opportunities to reduce severe immunosuppression in patients already attending for HIV care."

 

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

Personalized Medicine Advancing Targeted Treatment Path

A comprehensive analysis of how genomic insights, biomarker research, and data-driven precision therapies are transforming the traditional one-size-fits-all medical model into highly individualized patient care.

Medical Imaging Innovation Improving Diagnostic Accuracy

The rapid evolution of high-resolution sensors and intelligent algorithmic...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »